T-Cell Therapy

all catalysts(0)

nothing on the calendar yet

News(10)

• STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients
  The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.
  stat · 1mo ago
• FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
  The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
  onclive · 3mo ago
• FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
  The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.
  onclive · 3mo ago
• Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL
  Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.
  onclive · 3mo ago
• Consensus Recommendations Address Key Controversies in Lymphoma Management
  Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.
  onclive · 3mo ago
• BRUIN CLL-321 Trial Impact and Treatment Selection
  Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.
  onclive · 3mo ago
• Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy
  Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
  onclive · 3mo ago
• Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma
  Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.
  onclive · 3mo ago
• Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma
  Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.
  onclive · 3mo ago
• Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
  A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.
  onclive · 3mo ago